China could lose $485 billion in US exports by 2027 as tariffs rise, shifting trade flows to Russia, Vietnam, and others amid global supply rebalancing.
AstraZeneca’s $50 billion investment will expand US drug manufacturing and R&D, boosting innovation and creating new job opportunities in key locations.
